|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Japanese Drugmakers Strengthen Area Ties
10/19/2005 5:13:10 PM
Japanese drugmakers are keeping their roots firmly planted in the Chicago area.
Effective Friday, Astellas Pharma U.S. Inc. will list the address of its U.S. headquarters as Deerfield, the longtime home of Fujisawa Healthcare Inc.
The Astellas name replaces Fujisawa as a result of Fujisawa's recently completed merger with Yamanouchi Pharmaceutical Co. of Tokyo. Yamanouchi's U.S. headquarters had been in New Jersey but will now be in Deerfield.
Under the Astellas name, the combined Fujisawa-Yamanouchi operation has annual worldwide sales of about $8 billion, putting the company among the top 20 drugmakers in the world.
"As Astellas, we will build on nearly two centuries of collective experience to create a unique place in the U.S. pharmaceutical landscape, where true innovation is valued and rewarded," said Makoto Nishimura, chairman and chief executive of Astellas Pharma U.S. Inc.
In Japan, Astellas is second only to Takeda Pharmaceutical Co., which has more than $10 billion in annual worldwide sales. Like Astellas, Takeda has its U.S. base here, with offices in suburban Lincolnshire under the name Takeda Pharmaceuticals North America Inc. Takeda also owns half of Lake Forest-based TAP Pharmaceutical Products Inc., with partner Abbott Laboratories.
The United States has long been an important market for Japanese drugmakers, especially since there are no price controls in the U.S. as there are in their country, so selling drugs is more profitable here.
|
|
|
|
|
|
|
|
|
|
|